VOLUME 23 NUMBER 4 APRIL 2016 nature structural & molecular biology a r t i c l e s Molecular motors exert critical roles in virtually all cell processes. Myosin VI belongs to a superfamily of more than 20 different classes of actin-based motor proteins 1,2 that hydrolyze ATP to perform mechanical work and move cargos along actin tracks. The ability to walk toward the minus end of actin filaments makes myosin VI unique in the myosin family 3 . This unusual property appears to allow myosin VI to perform a number of specific cellular functions, such as clathrin-mediated endocytosis and vesicular transport 4,5 . Myosin VI was originally discovered in Drosophila, in which it participates in cell migration during ovary development 6 , spermatogenesis 7, 8 and neuroblast asymmetric division 9, 10 . In mammalian cells, myosin VI localizes to the Golgi complex, membrane ruffles at the leading edges of migrating cells, clathrin-coated pits at plasma membranes, APPL1-positive early endosomes and autophagosomes (reviewed in ref. 11). Detailed mechanisms underlying the function of myosin VI in these diverse processes are currently unclear.
a r t i c l e s Molecular motors exert critical roles in virtually all cell processes. Myosin VI belongs to a superfamily of more than 20 different classes of actin-based motor proteins 1,2 that hydrolyze ATP to perform mechanical work and move cargos along actin tracks. The ability to walk toward the minus end of actin filaments makes myosin VI unique in the myosin family 3 . This unusual property appears to allow myosin VI to perform a number of specific cellular functions, such as clathrin-mediated endocytosis and vesicular transport 4, 5 . Myosin VI was originally discovered in Drosophila, in which it participates in cell migration during ovary development 6 , spermatogenesis 7, 8 and neuroblast asymmetric division 9, 10 . In mammalian cells, myosin VI localizes to the Golgi complex, membrane ruffles at the leading edges of migrating cells, clathrin-coated pits at plasma membranes, APPL1-positive early endosomes and autophagosomes (reviewed in ref. 11) . Detailed mechanisms underlying the function of myosin VI in these diverse processes are currently unclear.
At a molecular scale, myosin VI consists of two functional domains ( Fig. 1a) : a motor-IQ domain sufficient for pointed end (minus end)-directed movement and a tail domain, which can be further divided into a long helical region, reportedly a coiled-coil domain, and a C-terminal globular region, known as a cargo-binding domain (CBD) . A motif interacting with ubiquitin 12 is located at the boundaries. The CBD contains two myosin VI ligand-interaction surfaces: the RRL and WWY motifs 11 . The RRL triplet is responsible for myosin VI binding to endocytic adaptors, including GAIP-interacting protein C terminus (GIPC) 13, 14 and autophagy receptors, such as optineurin 15 , nuclear dot protein 52 (NDP52) 16 and Traf6-binding protein (T6BP) 16 .
An intrinsic level of complexity in deciphering the functions of myosin VI comes from the presence of different isoforms. Two regions are alternatively spliced within the tail (Fig. 1a) , thus leading to an insertion between the helical domain and the CBD (large insert, LI) 17, 18 as well as an insertion at the C terminus (small insert, SI) 19 . Although myosin VI is widely expressed in most tissues, isoforms containing the LI are specifically found in polarized epithelial cells with well-developed apical microvilli 17, 20 . How the presence of LI in the tail influences the functions and intracellular targeting of myosin VI is unknown. Isoforms lacking the LI present no specific expression and localization but are required for polarized transport of tyrosine motif-containing basolateral membrane proteins 20 and for maintenance of an active pool of secretory granules near the plasma membrane in neurosecretory cells 19 .
The role of myosin VI in cell migration has been linked to ovarian 21 and prostate cancers [22] [23] [24] , in which myosin VI overexpression correlates with clinically aggressive behavior. Notably, silencing of myosin VI expression decreases the migratory potential and the malignant properties of ovarian 21 and prostate cancer cell lines 21, 22 .
In this study, we set out to investigate the major splicing event occurring in myosin VI from molecular and functional perspectives. selection for this isoform in tumor progression and metastasis (Fig. 1c) . We then examined a number of ovarian cancer cell lines for myosin VI isoform expression, to identify possible cellular models for in vitro studies. OVCAR-5 was unique among the cell lines examined because it expressed all myosin VI isoforms, whereas the remaining six cell lines selectively expressed isoform 2 (Fig. 1d) .
Knocking down myosin VI substantially inhibits migration in vitro and reduces the dissemination of ovarian tumor cells propagated in nude mice 21 . To gain insight into the possible advantages derived from overexpression of myosin VI isoform 2 in cancer cells, we examined cell migration as an important feature of cancer metastasis. We analyzed the effects of myosin VI depletion in SK-OV-3, HEY and OVCAR-5 cell lines in wound healing assays. Depletion of myosin VI was complete and comparable in all cell lines (Fig. 1e) . In the absence of myosin VI, SK-OV-3 and HEY cells were severely impaired in their ability to migrate and to close wounds, whereas the migration efficiency of OVCAR-5 cells was unaffected ( Fig. 1e and Supplementary Movies 1-3) . We obtained comparable results with different oligonucleotides ( Supplementary  Fig. 2 ). Hence, only ovarian cancer cells that selectively expressed myosin VI isoform 2 were deficient in cell migration after depletion of myosin VI. 
Ovarian primary tumours a r t i c l e s npg a r t i c l e s Next, we examined possible partners of myosin VI in this process. In A549 cells, ablation of myosin VI or its interactor optineurin 15 inhibits polarized delivery of the epidermal growth factor receptor into the leading edge and leads to profound defects in lamellipodia formation 25 . These findings prompted us to test the effect of optineurin depletion in our model system. Optineurin knockdown reduced the migration ability of SK-OV-3 but did not further decrease cell speed in myosin VI-depleted cells (Fig. 2a,b and Supplementary Movie 4). The lack of additive effects suggests that the two proteins act along the same axis.
Our functional data suggested that optineurin may specifically interact with myosin VI isoform 2. Optineurin binding requires the RRL motif 15 of myosin VI, which lies outside of the splicing region (Fig. 2c) . Nonetheless, we tested its binding by using as a bait a larger region (myosin VI 998-1131 ; amino acid numbering from isoform 3) that distinguishes the different isoforms (Fig. 2c) . Optineurin specifically bound to isoform 2 and to a shorter construct lacking the alternatively spliced region (1080-1131) (Fig. 2d) . This result prompted us to test for a possible preference of the other known RRL interactors: GIPC 13 , NDP52 (ref. 16 ) and T6BP 16 . Surprisingly, all three interactors showed a clear preference for isoform 2, which lacks the large insert (Fig. 2c) .
Myosin VI isoforms display different interaction partners
Distinct functions for myosin VI isoforms have been described, but no molecular rationale for such differences has been provided 17, 20 . The results obtained with the RRL interactors prompted us to hypothesize that the various myosin VI isoforms may have different interactomes. Thus, we performed a mass spectrometry-based proteomic screen aimed at comparing the interaction profiles of the various isoforms. We used GST-tagged myosin VI 998-1131 constructs in pulldown assays with HEK293T cellular lysates (Fig. 2e) . We then performed a label-free quantitative experiment and analyzed the resulting data with MaxQuant software. Inspection of the gel (Fig. 2e) indicated that isoforms 1 and 3 have almost identical binding partners, a result confirmed by data presented in Table 1 . Most of these binding movies for mock and myosin VI knockdown; n = 39 movies for optineurin knockdown; n = 25 movies for double knockdown); a.u., arbitrary units. Data are from three independent cell cultures). ****P < 0.0001; ***P < 0.001; NS, no significant difference by two-tailed t test. (c) Amino acid sequence alignment covering the region amplified by RT-PCR. Numbering on top of the sequence alignment refers to isoform (iso) 3. The RRL motif is highlighted in red; secondary-structure elements are depicted at top. The linker region that varies between the short (iso2) and the long (iso1 and iso3) isoforms is boxed in orange. a r t i c l e s partners have been implicated in endocytosis and vesicular trafficking and are not shared by isoform 2. Isoform 2-specific interactors were more heterogeneous and comprised nuclear factors, an E3 ligase (DDB1-DCAF1) and several GEFs, including the previously identified myosin VI-binding partner DOCK7 (ref. 26) . Few interactors common to all three isoforms (for example, COPB2) were also identified. Examples of the top hits for each class are provided in Table 1 . None of the previously characterized RRL interactors were present. Because its molecular weight is lower than that of the GST-fusion proteins, GIPC was automatically excluded from the analysis, whereas NDP52 and T6BP were identified with a single peptide and thus were filtered out (complete list of proteins differentially interacting with isoforms 1-3 versus GST control in Supplementary Table 1) .
Experimental validation confirmed the most abundant identified interactors (five out of five tested) and their specificity (Fig. 2f) . Because isoforms 1 and 3 showed no difference in terms of interaction networks, we refer to them collectively as myosin VI long and use myosin VI short to indicate isoform 2.
Structure of the myosin VI long clathrin-binding domain
The interactome analysis identified clathrin heavy chain (CLTC) as a major specific binding partner of myosin VI long ( Table 1 and Fig. 2f) . It is well known that myosin VI and clathrin form a ternary complex with the Dab-2 adaptor 27, 28 . However, neither the WWY motif of myosin VI (ref. 27 ) nor the larger surfaces implicated in binding to Dab-2 (ref. 28) were present in the constructs used for the proteomic screening. Thus, we inferred that myosin VI may also interact with clathrin directly.
To map this new interaction surface, we generated a panel of GST-tagged deletion constructs and tested their interaction with endogenous clathrin starting from isoform 3 myosin VI 998-1131 , which we used for the proteomic screen ( Supplementary Fig. 3a-c) .
Regions deleted from the C-terminal end did not show any clathrin binding ( Supplementary Fig. 3a) , whereas fragments deleted at the N-terminal end retained clathrin interaction ( Supplementary Fig. 3b ). The minimal binding region appeared to be 1055-1131, which includes part of the isoform-specific LI region (Fig. 2c) and the region directly following it. Further N-terminal shortening, or even a small internal deletion, disrupted binding ( Supplementary Fig. 3b,c) .
We used NMR techniques to solve the structure of the clathrin-binding surface (Fig. 3a) . The 20 calculated NMR structures with the lowest energy from 100 starting structures converged well (stereo view in Supplementary Fig. 3d ) with a backbone r.m.s. deviation of 0.18 Å, after the exclusion of an 11-amino acid flexible loop directly after the LI (Supplementary Fig. 3d and Table 2 ). In the isoform-specific LI region, residues 1055-1068 form an amphipathic α-helix (α2-linker; Fig. 2c and Supplementary  Fig. 3e ) that packs against two other helices, α3 and α4, which are present in all isoforms (Fig. 3a) . Interaction between the isoform-specific α2-linker and the common helices α3 and α4 (denoted α3/α4) is defined by 106 NOE interactions, as exemplified for L1118 (Supplementary Fig. 3f) . A hydrophobic surface of the α2-linker formed by M1058, M1062, and L1066 inserts into a cleft formed by the α3-α4 interface and interacts with hydrophobic residues Y1091, F1114, L1118 and Y1121 (Fig. 3a,c) . In addition, a salt bridge occurs between α2-linker E1061 and α3 R1095 (Fig. 3b) .
Mutually exclusive association of clathrin and RRL binders
The RRL motif is embedded in helix α4 of the clathrin-binding domain (Fig. 2c) . As visible in the structure, two residues of the RRL motif were not accessible for binding with interactors ( Fig. 3d) , thus explaining their specificity for binding only myosin VI short (Fig. 2d) . L1118 is buried in the interface between the α2-linker and α3/α4 (Fig. 3c,d) , whereas R1117 forms a salt bridge with S1087 of the α3 (Fig. 3d) . We generated single point mutations of the RRL motif as well as the triple AAA mutation previously used to validate interactions with known myosin VI binders 13, 16 in the context of a myosin VI long fragment. R1117A (RAL), L1118A (RRA) and the triple AAA mutation abrogated the ability of myosin VI 998-1131 to pull down clathrin from cell lysates, whereas the R1116A (ARL) mutant behaved like the wild type (Fig. 3e) . Circular dichroism data of the R1117A-containing fragment ( Supplementary Fig. 3g ) revealed that R1117 is required for structural integrity of this myosin VI region.
The structural data provided an explanation for the myosin VI short selective interaction of RRL binders ( Fig. 2d) but implied that the triple AAA mutation (including R1117) is inappropriate to validate interactor binding 13, 16 . Thus, we probed the ability of all RRL interactors to interact with a myosin VI fragment carrying single point mutations in the RRL motif. We used a minimal fragment (G1080-R1131) that included α3/α4 but lacked the α2-linker and retained binding (Fig. 2d) . As for clathrin, and consistently with the structural data, the destabilizing R1117A mutation either alone or in the context of the AAA mutant impaired binding to partners (Fig. 3f) . Analyses performed with the other single point mutants demonstrated that R1116 and L1118 are critical for binding of GIPC and optineurin, npg a r t i c l e s whereas T6BP and NDP52 associate with myosin VI 1080-1131 in an RRL-independent fashion (Fig. 3f) . Together, these data implied that packing of the α2-linker against the α3/α4 helices in myosin VI long determined both the protein's exquisite clathrin-binding ability and its impairment in RRL-mediated binding (e.g., to optineurin). We sought to validate the functional effects of the myosin VI long conformation by testing point mutations disrupting the interaction between α3/α4 and the α2-linker. We replaced M1062, which is sandwiched between α3 and α4 (Fig. 4a) , with glutamine and used pulldown assays to evaluate this variant together with the previously characterized L1118A mutant (Fig. 3e) for binding to RRL-specific interactors. M1062Q was impaired in clathrin binding, similarly to L1118A. Strikingly, GIPC and optineurin gained binding to M1062Q but not to L1118A (Fig. 4b) , results consistent with the evidence that L1118 is within their interaction surface (Fig. 3f) . Finally, NDP52 and T6BP interacted with both mutants at levels similar to that of myosin VI short (Fig. 4b) . Thus, these point mutations induced a conformational change that converts a myosin VI long into a myosin VI short -like protein. NMR data of the L1118A mutant further validated this conclusion (Supplementary Fig. 3h ). These results confirm the conformational differences between the myosin VI isoforms induced by the presence of the α2-linker and establish their mutually exclusive association with clathrin and RRL interactors (e.g., optineurin) (Fig. 4c) .
To functionally evaluate these findings, we generated GFP-tagged versions of full-length myosin VI long wild type and L1118A and M1062Q mutants. For controls, we used myosin VI short and a myosin VI long mutated in the WWY motif (W1192L) and impaired in Dab-2 binding 13 . We transfected the constructs into HeLa cells in which we had knocked down endogenous myosin VI to avoid confounding effects due to the presence of the endogenous protein (e.g., dimerization). The results showed that endogenous clathrin was immunoprecipitated by myosin VI long but not by myosin VI short and that L1118A and M0162Q mutations abrogated this interaction (Fig. 4d) . In this context, the W1192L mutant showed binding comparable to that of wild-type myosin VI long (Fig. 4d) , thus suggesting that Dab-2 is dispensable for stable interaction with clathrin. We also analyzed the behavior of the isoforms by immunofluorescence. As previously reported 17 , myosin VI long strongly colocalized with clathrin, whereas myosin VI short exhibited no significant colocalization (Fig. 4e,f) . Notably, W1192L, L1118A and M1062Q mutants failed to colocalize with clathrin, similarly to myosin VI short (Fig. 4e,f) . We obtained similar results with myosin VI tails ( Supplementary Fig. 4) , which recapitulate myosin VI interaction and localization 17 . Together, these findings led us to conclude that, in addition to the known Dab-2-binding motif, a second isoform-specific binding surface drives the interaction of myosin VI long with clathrin. 
Exon skipping in myosin VI is common in cancer Our findings revealed that the isoform-specific α2-linker defines the specific conformation (Fig. 3a) , interaction ( Fig. 4d) and localization (Fig. 4e,f) of myosin VI isoforms. During in vitro epithelial cell polarization, a myosin VI isoform switch occurs toward longer isoforms 17, 18 , thus suggesting that myosin VI long is necessary for clathrin-mediated endocytosis in fully polarized cells. Because loss of cell polarity is a hallmark of cancer, we extended our analyses of myosin VI isoform expression to other cancer types by using an in silico approach. We evaluated the relative expression of the isoforms by exploiting the presence of exon 31, which encodes the α2-linker (outlined in Supplementary Fig. 1a) Supplementary Fig. 1b) .
The box plot relative to the overall analysis (Fig. 5a) showed that exon 31 skipping was a common event occurring with significantly increased frequency in tumor samples compared to normal samples. Thus, myosin VI short is selectively expressed in tumors. The analysis conducted at the level of single cancer types showed that exon skipping was highly frequent among certain tumors but not others (Supplementary Fig. 5 ) and suggested that the function of myosin VI short may be critical and positively selected only in specific types of cancers. Notably, in the case of ovarian cancer, no 'normal' controls were present in the database, but in comparison to the average of normal samples, exon E31RA was scarcely measurable (Fig. 5b) , thus further confirming the data obtained in primary tumors (Fig. 1c) . As proof of principle, we analyzed two breast cell lines, MCF10A and MDA-MB-231; the latter showed high levels of only myosin VI short in both sparse and confluent conditions (Fig. 5c) . After myosin VI depletion, MDA-MB-231 cells displayed a clear impairment in wound closure (Fig. 5d and Supplementary  Movie 5) , whereas MCF10A cells were unaffected (Fig. 5e and  Supplementary Movie 6) . Thus, cancer cells that selectively express 
DISCUSSION
The presence of myosin VI splice variants has led to the suggestion that they are directly responsible for disparate myosin VI functions, but no data have confirmed this hypothesis 11, 29 . Dab-2 is considered to be the adaptor that links myosin VI to clathrin-mediated function 13, 27, 30 . The Dab-2-myosin VI interaction, however, fails to explain the myosin VI long -specific interaction with clathrin 17 , because the Dab-2-binding region lies outside of the alternatively spliced regions 13, 27 . We provided what is to our knowledge the first rationale for clathrin selectivity, because the presence of the isoform-specific α2-linker, together with the following region defines a new clathrin-binding domain and dictates isoform-specific interactions. This finding has important functional implications. During epithelial cell polarization, an isoform switch of myosin VI occurs 17, 20 . In this context, cells acquire myosin VI long , which is recruited, possibly via clathrin interaction, to the apical part of polarized cells 17 . Here, myosin VI long may provide the coated vesicles with the required mechanical force to pass through the intricate meshwork of cortical actin 29 .
Our study also offers a new perspective on the molecular mechanism that regulates the monomer-dimer conversion of this anchor-motor protein 31, 32 . The distinct interaction surfaces for clathrin and Dab-2, both of which are required for colocalization with clathrin-coated pits (Fig. 4e,f) may act synergistically to regulate myosin VI's motor ability. Clathrin binding may recruit and concentrate myosin VI at clathrin-coated pits, where Dab2 may tether it into a stable and active dimer, which is crucial in converting myosin VI into a cellular transporter 28 .
Unexpectedly, our data showed a clear preference of RRL interactors toward myosin VI short . In the case of optineurin and GIPC, the structural basis for this specificity was revealed because R1116 and L1118, which are part of the interaction surface, were masked in the myosin VI long conformation. A similar explanation may also apply for NDP52 and T6BP, although their precise interaction surface remains to be established. In any case, our data suggested that myosin VI short is the isoform specifically involved in the functional interaction with these adaptor proteins, which have an established role in autophagy 33 .
Myosin VI has been implicated in cell migration in both Drosophila and mammals (reviewed in ref. 34 ). However, published data have led to an intriguing conundrum. On the one hand, myosin VI depletion from epithelial cells leads to loss of vinculin from adhesion sites and weakens E-cadherin complexes 35 . Such rearrangement results in loss of cohesive forces in epithelial layers, a well-known prerequisite for invasive cancer-cell migration. On the other hand, myosin VI is markedly upregulated in prostate and ovarian cancer cells, in which its overexpression correlates with aggressive clinical behavior 21, 22 . In this context, silencing of myosin VI expression in ovarian and prostate cancer cell lines decreases the migratory potential of these cells in vitro and ovarian tumor dissemination in vivo 21, 22 . Our results provided a molecular explanation for this conundrum, ascribing the cohesive and migratory defects to the two different myosin VI isoforms. We found that myosin VI short is overexpressed in ovarian and other invasive cancers, whereas myosin VI long is expressed in polarized epithelial cells, in which it probably promotes E-cadherin stabilization at cell-cell junctions. 
npg a r t i c l e s
In Drosophila, migration of the border cells occurring during oogenesis is reminiscent of tumor cell invasion 21 . Initially, the border cells are polarized epithelial cells with strong cell-cell contacts. For migration to begin, cell polarity changes from apicobasal to front-rear, and proteins found at cell-cell junctions reorganize at the invasive edge of the cell, where they facilitate motility and invasion 36 . During these events, myosin VI changes localization from the basolateral membrane to membrane ruffles at the front edges of moving cells 36 . An interesting possibility is that at the onset of border-cell migration, an isoform switch toward the shorter myosin VI isoform occurs. Nothing is known about the differential expression and functions of myosin VI isoforms in Drosophila. However, we found that different splicing variants also exist in the fly. Secondary structure-prediction analysis suggested that, even if the primary sequence is not conserved, the exon that is skipped in the shortest isoforms encodes an α-helix with length and position similar to those of the α2-linker in mammals (Supplementary Fig. 6 ).
Our data suggest that cancer cells positively select myosin VI short because it confers them with a migratory advantage. The exact molecular mechanism through which myosin VI short modulates cell migration remains to be established. Here, we substantiated previous findings 25 , providing genetic evidence that the autophagic RRL binder optineurin acts in the same pathway (Fig. 2a,b) . In addition, we demonstrated that myosin VI has a new ubiquitin-binding domain 37 that probably contributes to optinerurin interaction and to the migratory function of myosin VI short .
The contribution of alternative splicing in human diseases is widely recognized 38 . Unbalanced expression of splicing variants or a failure to properly express the correct isoform is clearly part of cancer cell biology 39 . Cancer-associated alternative-splicing variants are considered to be new tools for the diagnosis and classification of cancers and may become targets for innovative therapeutic interventions based on highly specific splicing-correction approaches. The selective expression of myosin VI short in cancer fits very well in this context. This unexpected finding paves the way for defining the splicing mechanism of myosin VI and provides an exciting starting point to understand and therapeutically exploit new key events in pathological cell migration.
METHODS
Methods and any associated references are available in the online version of the paper. 
ONLINE METHODS

Materials and reagents.
Human myosin VI cDNA KIAA0389 (isoform 1) was obtained from Kazusa DNA Research Institute and was PCR amplified and cloned into pGEX 6P1 (Amersham Pharmacia Biotech), FLAG-pcDNA3.1 (Invitrogen) and pEGFP-C2 (Clontech). Myosin VI isoform 2 and isoform 3 were generated by mutagenesis (deletion and insertion, respectively) with isoform 1 as template and the primers shown in Supplementary Table 2. All other constructs described were engineered by site-directed mutagenesis or recombinant PCR and sequence verified. Details are available upon request.
Cell lines, sources and medium compositions are listed in Supplementary  Table 3 . At each batch freezing, all cell lines were authenticated by STR profiling (StemElite ID System, Promega) and tested for mycoplasma with PCR and biochemical testing (MycoAlert, Lonza).
GFP-PI3KC2α was kindly provided by E. Hirsch, SFB-DDB1 by S. Maddika, GFP-optineurin by A. Israel, FLAG-T6BP by F. Buss, His-GIPC by G. Serini, and FLAG-NDP52 by F. Randow.
Antibodies used (along with sources, catalog numbers and dilutions) are listed in Supplementary Table 3 . Commercial antibodies were validated by the manufacturers. The homemade anti-myosin VI and anti-GFP rabbit polyclonal antibodies were produced by Eurogentech S.A., affinity purified by Cogentech and validated by immunoblotting (Fig. 1e) or by immunofluorescence (Supplementary Fig. 4a ).
Myosin VI knockdown. Transient knockdown of myosin VI and optineurin was performed with Stealth siRNA oligonucleotides (ThermoFisher). Cells were transfected with RNAiMax (Invitrogen) at 8 nM final concentration according to the manufacturer's instructions. For double knockdown, single oligos were used at a final concentration of 4 nM each. Two oligonucleotides (shown in Supplementary Table 2) were used with comparable results. HeLa cells stably knocked down for myosin VI were generated with a pSUPER vector bearing the shRNA shown in Supplementary Table 2, targeting a sequence in the motor domain.
Immunofluorescence and colocalization experiments. For immunofluorescence analysis, cells were fixed with 4% paraformaldehyde for 10 min and permeabilized at room temperature with 0.1% Triton X-100. Cells were incubated with primary antibodies for 1 h, and this was followed by incubation with secondary antibodies for 30 min at room temperature. Coverslips were mounted in a glycerol solution (20% glycerol and 50 mM Tris, pH 8.4) to avoid mechanical deformation of the sample. Images were captured with a Leica inverted SP2 microscope with a laser-scanning confocal system. Analysis was performed with ImageJ (http://imagej.nih.gov/ij/).
For colocalization experiments in HeLa cells, to remove soluble cellular proteins, cells were extracted with 0.03% saponin in cytosolic buffer (25 mM HEPES-KOH, pH 7.4, 25 mM KCl, 2.5 mM magnesium acetate, 5 mM EGTA, and 150 mM K-glutamate) for 1 min before fixation. For colocalization analysis, ROIs drawn around individual cells (n = 15 from two independent experiments) were analyzed. Pearson's and Manders's coefficients were obtained with the JACoP plugin and processed for statistical analysis with Prism (GraphPad software). Statistical significance was determined with nonparametric two-tailed t tests. Sample sizes were chosen arbitrarily with no inclusion and exclusion criteria. The investigators were not blinded to the group allocation during the experiments and data analysis.
Isoform detection by PCR. Expression of myosin VI isoforms in various cell lines was assessed by PCR. mRNA was isolated from cells grown on plastic dishes by use of TRIzol reagent (Invitrogen) and an RNeasy Mini Kit (Qiagen) according to the manufacturers' protocols. RNA retrotranscription of genomic DNA was performed with a QuantiTect Reverse Transcription Kit (Qiagen). The cDNA obtained was used in PCR reactions with primers flanking the spliced regions (Supplementary Table 2 ). Original images of gels in this study can be found in Supplementary Data Set 1.
Wound healing assay. 3 × 10 4 cells were plated into each chamber of a CultureInsert for wound healing (Ibidi) 48-72 h before the beginning of the experiments. After insert removal, images of cells were acquired every 5 min for 24 h. Live-cell imaging was performed with an ORCA-ER camera (Hamamatsu) on an Olympus IX81 automatic microscope equipped with closed heating and CO 2 perfusion devices. Data analysis was performed automatically with ImageJ (http://rsb.info.nih.gov/ij/) and a script designed to distinguish and measure the wound area from the area covered by cells. Wound closure rates correspond to the normalized slopes of linear equations derived from regression analyses of the area-over-time plots. Statistical significance was determined by nonparametric two-tailed t tests. Sample sizes were chosen arbitrarily with no inclusion and exclusion criteria. The investigators were not blinded to the group allocation during the experiments and data analysis.
Protein expression and purification. GST fusion proteins were expressed in E. coli Bl21(DE3) Rosetta at 18 °C for 16 h after induction with 1 mM IPTG at an OD 600 of 0.5. Cell pellets were resuspended in lysis buffer (50 mM Na-HEPES, pH 7.5, 150 mM NaCl, 1 mM EDTA, 5% glycerol, 0.1% NP-40, and Protease Inhibitor Cocktail set III, Calbiochem). Sonicated lysates were cleared by centrifugation at 20,000 r.p.m. for 30 min. Supernatants were incubated with 1 ml of glutathione-Sepharose beads (GE Healthcare) per liter of bacterial culture. After 2 h at 4 °C, the beads were washed with PBS/0.1% Triton and equilibrated in storage buffer (50 mM Tris, pH 7.4, 100 mM NaCl, 1 mM EDTA, 1 mM DTT, and 10% glycerol).
Biochemical experiments. For pulldown experiments, 2 µM of GST-fusion proteins immobilized onto GSH beads were incubated for 1 h at 4 °C in JS buffer (50 mM HEPES, pH 7.5, 50 mM NaCl, 1.5 mM MgCl 2 , 5 mM EGTA, 5% glycerol and 1% Triton X-100) with either 1 mg of HEK293T cellular lysate or 200 µg of transfected HEK293T cellular lysate. Detection was performed by immunoblotting with specific antibodies. Ponceau-stained membranes were used to show loading of GST-fusion proteins.
For coimmunoprecipitation (co-IP) experiments, HeLa cells stably knocked down for myosin VI were transfected with Lipofectamine 2000 (Life Technologies) according to the manufacturer's instructions, and IP was performed with 500 µg of lysate and GFP-Trap (Chromotek) in JS buffer. Original images of blots showed in this study can be found in Supplementary Data Set 1.
Liquid chromatography-tandem MS (LC-MS/MS) analysis.
Proteins were resolved by SDS-PAGE on a gradient gel (4-12% TGX precast gel, Bio-Rad) and stained with colloidal blue (Colloidal Blue Staining Kit, Invitrogen).
Each lane was divided into five slices above the location of GST-fusion proteins (Fig. 2e) and was digested with trypsin. Proteins with a molecular mass lower than 50 kDa were automatically excluded from the analysis (including the RRL interactor GIPC, 36 kDa). Briefly, samples were subjected to reduction in 10 mM DTT for 1 h at 56 °C. Digestion was carried out by saturating the gel with 12.5 ng/µL sequencing-grade modified trypsin (Promega) in 50 mM ammonium bicarbonate overnight. Peptide mixtures were acidified with trifluoroacetic acid (TFA, final concentration 3%), extracted from gel slices with 30% acetonitrile (ACN)/ 3% TFA, dried in a Speed-Vac and resuspended in 20 µL of 0.1% FA. Three technical replicates of 5 µL injected for each sample were analyzed on a Fouriertransformed LTQ mass spectrometer (Thermo Electron). Peptide separation was achieved by a linear LC gradient from 100% solvent A (5% ACN and 0.1% formic acid) to 20% solvent B (0.1% formic acid in ACN) over 33 min and from 20% to 80% solvent B in 4 min at a constant flow rate of 0.3 µL/min on an Agilent chromatographic separation system 1100 (Agilent Technologies) equipped with a 15-cm fused-silica emitter with 75-µm inner diameter (New Objective), packed in-house with ReproSil-Pur C18-AQ 3 µm beads (Dr. Maisch) with a highpressure bomb loader (Proxeon). Survey MS scans were acquired in the FT from m/z 350-1,650 with 100,000 resolution. The five most intense doubly and triply charged ions were automatically selected for fragmentation. Target ions already selected for the MS/MS were dynamically excluded for 60s.
Data processing and protein quantification. Raw MS files were converted into peaklist (.msm files); all MS/MS samples were analyzed with Mascot (Matrix Science, version 2.3.02) set up with the following parameters: UniProt_ CP_Human_20140416 database (88,708 entries), taxonomy, Homo sapiens; enzyme, trypsin; maximum missed cleavages, 2; fixed modification, carbamidomethyl cysteine; variable modifications, methionine oxidation and acetyl (protein N terminus); peptide tolerance, 10 p.p.m.; MS/MS tolerance, 0.5 Da; instrument, ESI-TRAP.
npg
Interactomics results were generated with Scaffold_4.3.4 (Proteome Software), and protein quantification was displayed as total spectral count (best candidates in Table 1 ). Peptide identifications were accepted if they could be established at greater than 95.0% probability by the Peptide Prophet algorithm with Scaffold delta mass correction 40 . Protein identifications were accepted if they could be established at greater than 99.0% probability and contained at least two identified peptides. Two RRL interactors, T6BP and NDP52, were excluded at this step, owing to single peptide identification. Protein probabilities were assigned with the Protein Prophet algorithm 41 . Proteins that contained similar peptides and could not be differentiated by MS/MS analysis alone were grouped to satisfy the principles of parsimony. Proteins sharing marked peptide evidence were grouped into clusters.
Label-free quantification was obtained with MaxQuant software (1.4.0.5). MS/MS peak lists were searched against the Uniprot_cp_human_2013_07 database, in which trypsin specificity was used, and up to two missed cleavages were allowed. Searches were performed by selecting alkylation of cysteine by carbamidomethylation as a fixed modification and oxidation of methionine and N-terminal acetylation as variable modifications. The mass tolerance was set to 20 p.p.m. and 0.5 Da for parent and fragment ions, respectively. The false discovery rate for both peptides and proteins was set at 0.01. Additionally, we required at least two peptide identifications per protein, of which at least one was unique. LFQ intensities, which are the intensity values normalized across the entire data set, were used for quantification on the basis of unique plus razor peptides. Statistical analysis was performed with Perseus. Proteins were filtered with the Benjamini-Hochberg procedure and t tests. Proteins that differentially interacted with isoform 1, isoform 2 and isoform 3 versus GST control are reported in Supplementary Table 1 . The proteomic data as raw files, total proteins and peptides identified with relative intensities and search parameters have been deposited on PeptideAtlas repository (accession code PASS00591).
NMR spectroscopy. The NMR data were acquired at 10 °C on Bruker 700, 800 and 850 MHz spectrometers equipped with gradient cryoprobes. 15 N-or 13 C-15 N-labeled samples used for titration experiments ranged from 0.1 to 0.2 mM, whereas experiments acquired for structure determination were performed with 0.5 to 0.8 mM samples; all experiments were conducted in 20 mM sodium phosphate buffer, pH 6.5, 50 mM sodium chloride, 2 mM DTT, 0.01% NaN 3 , and 10% 2 H 2 O/90% 1 H 2 O. 2D [ 1 H, 15 N] HSQC and 3D HNCO, HN(CA)CO, HNCA, HN(CO)CA, HNCACB and CBCA(CO)NH spectra were used for backbone 1 H, 15 N, and 13 C assignments. Side chain 1 H and 13 C assignments were obtained by 2D [ 1 H, 13 C] HSQC and 3D HBHA(CO)NH, H(CCCO)NH, (H)CC(CO)NH, HCCH-COSY, HCCH-TOCSY and (H)CCH-TOCSY spectra. Assignments were checked for consistency with 3D 15 N-13 C NOESY-HSQC spectra recorded with mixing times of 120 or 100 ms.
Structure determination. Statistics for the structure calculations for myosin VI 1050-1131 are displayed in Table 2 . The regions for Ramachandran-plot statistics and r.m.s. deviation calculations include T1054-R1068 and Y1084-S1126. NMR spectra were processed with NMRPipe and analyzed with KUJIRA 42 and SPARKY. CYANA2.1 (ref. 43 ) was used for automated NOE assignment and to calculate the structures by torsion-angle dynamics; each NOE assignment was manually inspected and confirmed or corrected. Dihedral-angle restraints were derived by TALOS 44 . A total of 100 structures were independently calculated, and the 20 conformers with the lowest target-function values were selected for refinement with Xplor-NIH. Structures were evaluated with PROCHECK-NMR 45 and visualized with MOLMOL 46 , and the figures were generated with PyMOL (http:// www.pymol.org/). The quality of the structures is also reflected by the distribution of 94.6% and 5.4% of the backbone torsion angles in the most-favored and additionally allowed regions of the Ramachandran plot, respectively, as calculated by PROCHECK_NMR.
Isolation, culture and processing of primary epithelial ovarian cancer cells. Patient-derived tissue samples were collected with the approval of the Ethical Committee of the European Institute of Oncology. Fresh biopsies of ovarian cancer were obtained from patients with high-grade epithelial ovarian serous carcinoma who had undergone surgical tumor debulking. Fresh biopsies of normal ovaries were obtained after informed consent had been granted from patients undergoing adnexectomy for nonovarian gynecological pathologies.
All tumors were digested in DMEM/F12 medium (Gibco) containing 2 mM glutamine, 1% penicillin/streptomycin, 200 U/ml collagenase IA and 100 U/ml hyaluronidase. Normal ovaries were digested in 5U/ml dispase for 30 min at 37 °C, and then the organ surfaces were scraped to isolate the epithelial cells. The derived primary epithelial cells were maintained in monolayer adherent cultures in collagen I Cellware coated flasks (Corning) in DMEM/F12 medium (Gibco) containing 1% FBS, 2 mM glutamine, 1% penicillin/streptomycin, 0.2% gentamicin, 0.2% amphotericin, 10 mg/ml transferrin, 1 mg/ml insulin, 1 mg/ml hydrocortisone, 10 mM HEPES, pH 7.5, 50 mM ascorbic acid, 15 nM sodium selenite, 50 ng/ml cholera toxin, 10 nM EGF, 35 mg/ml bovine pituitary extract, 10 nM T3 and 10 nM β-estradiol. For RNA extraction, 5 × 10 6 primary cells were washed in PBS, and the cell pellets were snap frozen in dry ice.
RNA-seq analysis. RNA-seq exon quantification data were downloaded from the TCGA Data Portal (http://tcga-data.nci.nih.gov/tcga/dataAccessMatrix. htm). Downloaded files included experiments that were analyzed with the pipeline 'RNAseq' and conducted on neoplastic cells belonging to ten different tissues: bladder urothelial carcinoma (BLCA), breast invasive carcinoma (BRCA), esophageal carcinoma (ESCA), head and neck squamous cell carcinoma (HNSC), kidney renal clear cell carcinoma (KIRC), liver hepatocellular carcinoma (LIHC), lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), stomach adenocarcinoma (STAD) and uterine corpus endometrial carcinoma (UCEC). Control experiments were also downloaded for each neoplastic counterpart. Additionally, experiment files relative to four additional neoplastic tissues were considered: colon adenocarcinoma (COAD), kidney renal papillary cell carcinoma (KIRP), serous cystadenocarcinoma (OV) and rectum adenocarcinoma (READ). For these last four sets, control counterparts were not available. Despite the availability of RNA-seq data from acute myeloid leukemia (LAML), such files were discarded, owing to peculiar noncomparable exon notation. The resulting data set consisted of 293 control and 1,646 tumor samples belonging to 14 different tumor types. For each experiment, the exon quantification file was considered. The raw counts (RC) and RPKM values were extracted 47 Exon expression changes between cancer and normal samples were estimated with RPKM, a measure of expression that reflects the molar concentration of a transcript in the sample by normalizing read counts for mRNA length and for the total read number in the sample. Relative abundances of exon E31 (E31RA) were then obtained for each sample as the ratio of their RPKM and the average RPKM values of the four flanking constitutive exons (namely E27, E28, E32 and E33). E31-normalized relative abundances (E31NRA) were obtained for each cancer type as the ratio between each sample E31RA and the median E31RA value of the corresponding control samples. These normalized values could be compared among different cancer types. For cancer types with no matched control set, we obtained E31NRA as the ratio between each sample E31RA and the median E31RA value of all the control samples. Wilcoxon tests 48 were performed with the R package (http://www.R-project.org/) to verify the hypothesis that the log ratio between tumors and control samples E31NRA values was negative (i.e., the median E31NRA was less in tumors than that in controls). This analysis was performed for cancer types for which a control set was available as well as among all cancer types overall. 
